EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

An Updated Review of Membranous Nephropathy

Orhan Efe, Paolo Nikolai Hao So iD, Urmila Anandh, Edgar V Lerma iD, Nasim Wiegley iD

Indian Journal of Nephrology · 10.04.2024 · 34 · 105-118

DOI: 10.25259/ijn_317_23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Nephrology, online erschienen am 10.04.2024. Verfasst von Orhan Efe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Massachusetts General Hospital; Harvard Medical School, Boston, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in adults. The discovery of phospholipase A2 receptor (PLA2R) as a target antigen has led to a paradigm shift in the understanding and management of MN. At present, serum PLA2R antibodies are used for diagnosis, prognostication, and guiding treatment. Now, with the discovery of more than 20 novel target antigens, antigen mapping is almost complete. The clinical association of certain antigens provides clues for clinicians, such as the association of nerve epidermal growth factor-like 1 with malignancies and indigenous medicines. Serum antibodies are detected for most target antigens, except exostosin 1 and 2 and transforming growth factor-beta receptor 3, but their clinical utility is yet to be defined. Genome-wide association studies and studies investigating environmental factors, such as air pollution, shed more light on the underpinnings of MN. The standard therapy of MN diversified from cyclical cyclophosphamide and steroids to include rituximab and calcineurin inhibitors over the past decades. Here, we provide a cutting-edge review of MN, focusing on genetics, immune system and environmental factors, novel target antigens and their clinical characteristics, and currently available and emerging novel therapies in MN.

Schlagwörter

Stichwörter der Autor:innen

Membranous nephropathyPLA2R antibodiesemerging therapiesenvironmental factorsgenetic predispositionimmunosuppressiontarget antigens

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Massachusetts General Hospital; Harvard Medical School, Boston, USA.
  • Private Practice, Manila, Philippines.
  • Department of Nephrology, Amrita Hospitals, Faridabad, Delhi, NCR, India.
  • Department of Medicine, University of Illinois at Chicago; Advocate Christ Medical Center, Oak Lawn, Illinois, USA.
  • Division of Nephrology, Department of Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.

ORCID-Profile: Paolo Nikolai Hao So, Edgar V Lerma, Nasim Wiegley

Zitieren

APA

Efe, O., So, P. N. H., Anandh, U., Lerma, E. V., & Wiegley, N. (2024). An Updated Review of Membranous Nephropathy. Indian Journal of Nephrology, 34, 105-118. https://doi.org/10.25259/ijn_317_23

Vancouver

Efe O, So PNH, Anandh U, Lerma EV, Wiegley N. An Updated Review of Membranous Nephropathy. Indian Journal of Nephrology. 2024;34:105-118. doi:10.25259/ijn_317_23

BibTeX
@article{Efe2024,
  author = {Efe, Orhan and So, Paolo Nikolai Hao and Anandh, Urmila and Lerma, Edgar V and Wiegley, Nasim},
  title = {An Updated Review of Membranous Nephropathy},
  journal = {Indian Journal of Nephrology},
  year = {2024},
  volume = {34},
  pages = {105--118},
  doi = {10.25259/ijn_317_23}
}
Kostenlos starten →